Laura C Collins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9678272/publications.pdf

Version: 2024-02-01

87	5,343	126708	88477
papers	citations	33 h-index	70 g-index

89	89	89	8304
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell, 2015, 163, 506-519.	13.5	1,485
2	Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer. Breast Cancer Research, 2008, 10, R67.	2.2	275
3	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Modern Pathology, 2011, 24, 924-931.	2.9	275
4	Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer, 2005, 103, 1778-1784.	2.0	256
5	Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Modern Pathology, 2006, 19, 617-621.	2.9	201
6	Intracystic Papillary Carcinomas of the Breast: A Reevaluation Using a Panel of Myoepithelial Cell Markers. American Journal of Surgical Pathology, 2006, 30, 1002-1007.	2.1	182
7	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Research and Treatment, 2012, 131, 159-167.	1.1	180
8	Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Results in Breast Cancer. American Journal of Clinical Pathology, 2005, 123, 16-20.	0.4	161
9	Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia. Cancer, 2007, 109, 180-187.	2.0	136
10	Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Modern Pathology, 2006, 19, 172-179.	2.9	94
11	Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. International Journal of Cancer, 2016, 138, 2346-2356.	2.3	92
12	Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nursesâ€™ Health Studies. Breast Cancer Research, 2019, 21, 40.	2.2	81
13	Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer, 1998, 83, 2502-2508.	2.0	78
14	The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease. Cancer, 2006, 107, 1240-1247.	2.0	77
15	Alcohol Intake Between Menarche and First Pregnancy: A Prospective Study of Breast Cancer Risk. Journal of the National Cancer Institute, 2013, 105, 1571-1578.	3.0	72
16	Phenotypic Alterations in Myoepithelial Cells Associated With Benign Sclerosing Lesions of the Breast. American Journal of Surgical Pathology, 2010, 34, 896-900.	2.1	69
17	Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers. American Journal of Surgical Pathology, 2009, 33, 1093-1097.	2.1	68
18	Diagnostic Agreement in the Evaluation of Image-guided Breast Core Needle Biopsies. American Journal of Surgical Pathology, 2004, 28, 126-131.	2.1	66

#	Article	IF	Citations
19	Comparison of Estrogen Receptor Results From Pathology Reports With Results From Central Laboratory Testing. Journal of the National Cancer Institute, 2008, 100, 218-221.	3.0	65
20	Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Modern Pathology, 2007, 20, 1149-1155.	2.9	61
21	Breast cancer risk by extent and type of atypical hyperplasia: An update from the <scp>N</scp>urses' <scp>H</scp>ealth <scp>S</scp>tudies. Cancer, 2016, 122, 515-520.	2.0	54
22	Lobule type and subsequent breast cancer risk: Results from the Nurses' Health Studies. Cancer, 2009, 115, 1404-1411.	2.0	51
23	Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Research and Treatment, 2013, 139, 453-460.	1.1	50
24	Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Research and Treatment, 2011, 128, 243-250.	1.1	49
25	Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. Seminars in Diagnostic Pathology, 2015, 32, 362-369.	1.0	47
26	Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. Breast Cancer Research, 2010, 12, R61.	2.2	46
27	Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. Histopathology, 2016, 68, 138-151.	1.6	46
28	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal of Clinical Oncology, 2020, 38, 725-733.	0.8	46
29	HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Modern Pathology, 2005, 18, 615-620.	2.9	45
30	Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nursesâ€™ Health Study. Breast Cancer Research and Treatment, 2014, 147, 639-651.	1.1	45
31	Androgen Receptor Expression and Breast Cancer Survival: Results From the Nursesâ€™ Health Studies. Journal of the National Cancer Institute, 2019, 111, 700-708.	3.0	44
32	Predictors of local recurrence following excision alone for ductal carcinoma in situ. , 1999, 85, 427-431.		40
33	Radial scars and subsequent breast cancer risk: results from the Nursesâ€™ Health Studies. Breast Cancer Research and Treatment, 2013, 139, 277-285.	1.1	40
34	Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years. Cancer Research, 2016, 76, 5423-5430.	0.4	39
35	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	2.9	35
36	Intakes of Alcohol and Folate During Adolescence and Risk of Proliferative Benign Breast Disease. Pediatrics, 2012, 129, e1192-e1198.	1.0	34

#	Article	IF	Citations
37	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002.	2.3	31
38	Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational Method. Scientific Reports, 2017, 7, 43286.	1.6	31
39	Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nursesâ€™ Health Study. Breast Cancer Research and Treatment, 2017, 166, 613-622.	1.1	30
40	Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies. Cancer Prevention Research, 2016, 9, 732-738.	0.7	29
41	Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age. American Journal of Surgical Pathology, 2009, 33, 1802-1808.	2.1	27
42	Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. Npj Breast Cancer, 2017, 3, 39.	2.3	27
43	Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Caseâ€“Control Study. Annals of Surgical Oncology, 2015, 22, 502-508.	0.7	26
44	PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 798-806.	1.1	26
45	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	2.3	23
46	Benign breast lesions that mimic malignancy. Pathology, 2017, 49, 181-196.	0.3	22
47	Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Research, 2009, 11, R85.	2.2	21
48	Testosterone therapy and breast histopathological features in transgender individuals. Modern Pathology, 2021, 34, 85-94.	2.9	21
49	Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers. British Journal of Cancer, 2015, 113, 1104-1113.	2.9	20
50	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. Clinical Cancer Research, 2022, 28, 2339-2348.	3.2	20
51	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist, 2015, 20, 713-718.	1.9	19
52	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. British Journal of Cancer, 2022, 126, 302-309.	2.9	18
53	Ten-Year Risk of Diagnostic Mammograms and Invasive Breast Procedures After Breast-Conserving Surgery for DCIS. Journal of the National Cancer Institute, 2012, 104, 614-621.	3.0	17
54	Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast. Breast Cancer Research and Treatment, 2014, 145, 765-773.	1.1	17

#	Article	IF	Citations
55	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectrum, 2018, 2, pky063.	1.4	17
56	Precursor Lesions of the Low-Grade Breast Neoplasia Pathway. Surgical Pathology Clinics, 2018, 11, 177-197.	0.7	16
57	Deep learning assessment of breast terminal duct lobular unit involution: Towards automated prediction of breast cancer risk. PLoS ONE, 2020, 15, e0231653.	1.1	16
58	Adult Body Size and Physical Activity in Relation to Risk of Breast Cancer According to Tumor Androgen Receptor Status. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 962-968.	1.1	15
59	Sugar-Sweetened Beverages, Artificially Sweetened Beverages, and Breast Cancer Risk: Results From 2 Prospective US Cohorts. Journal of Nutrition, 2021, 151, 2768-2779.	1.3	13
60	Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms. Journal of Clinical Pathology, 2017, 70, 428-434.	1.0	12
61	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2021, 186, 157-165.	1.1	12
62	Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. American Journal of Managed Care, 2010, 16, 351-60.	0.8	12
63	Columnar Cell Lesions and Flat Epithelial Atypia of the Breast. Seminars in Breast Disease, 2005, 8, 100-111.	0.0	11
64	Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Research and Treatment, 2018, 170, 129-141.	1.1	11
65	Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2358-2368.	1.1	11
66	Deep Learning Image Analysis of Benign Breast Disease to Identify Subsequent Risk of Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa119.	1.4	11
67	Potential Role of Tissue Microarrays for the Study of Biomarker Expression in Benign Breast Disease and Normal Breast Tissue. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 438-441.	0.6	8
68	A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Research and Treatment, 2016, 159, 545-552.	1.1	8
69	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Caseâ€“Control Analysis Nested within the Nurses' Health Study II. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1264-1270.	1.1	7
70	Precision pathology as applied to breast core needle biopsy evaluation: implications for management. Modern Pathology, 2021, 34, 48-61.	2.9	7
71	Associations of reproductive breast cancer risk factors with breast tissue composition. Breast Cancer Research, 2021, 23, 70.	2.2	7
72	The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease. Npj Breast Cancer, 2021, 7, 23.	2.3	5

#	Article	IF	Citations
73	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. Modern Pathology, 2022, 35, 1370-1382.	2.9	5
74	Evaluation of significant genome-wide association studies risk â€" SNPs in young breast cancer patients. PLoS ONE, 2019, 14, e0216997.	1.1	4
75	Mucin Neovascularization as a Diagnostic Aid to Distinguish Mucinous Carcinomas From Mucocele-like Lesions in Breast Core Needle Biopsies. American Journal of Surgical Pathology, 2022, 46, 637-642.	2.1	4
76	Early-Life and Adult Adiposity, Adult Height, and Benign Breast Tissue Composition. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 608-615.	1.1	4
77	Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications. Journal of Pathology Informatics, 2022, 13, 100118.	0.8	4
78	Reply to breast cancer risk by the extent and type of atypical hyperplasia. Cancer, 2016, 122, 3088-3089.	2.0	3
79	Preface. Surgical Pathology Clinics, 2009, 2, ix.	0.7	2
80	Sexual orientation and benign breast disease in a cohort of U.S. women. Cancer Causes and Control, 2020, 31, 173-179.	0.8	2
81	Abstract P4-07-02: Clinicopathological features and BRCA 1/2 status in a large prospective cohort of young women with breast cancer. , 2020, , .		2
82	Flat Epithelial Atypia of the Breast. Surgical Pathology Clinics, 2009, 2, 263-272.	0.7	1
83	Less Common Variants and Mimics of DCIS. Surgical Pathology Clinics, 2012, 5, 529-544.	0.7	1
84	Sugar-Sweetened Beverages, Artificially Sweetened Beverages, and Breast Cancer Risk: Results From Two Prospective US Cohorts. Current Developments in Nutrition, 2021, 5, 276.	0.1	1
85	Triple-Negative/Basal-Like Breast Carcinomas. , 2016, , 431-443.		0
86	Contemporary Topics in Breast Pathology. Surgical Pathology Clinics, 2018, 11, ix.	0.7	0
87	TDLU Involution and Breast Cancer Riskâ€"Reply. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 798-798.	1.1	0